2024 Bloom Burton Award Finalist - Tom Frohlich formerly of Chinook Therapeutics

Tom Frohlich is a 2024 Bloom Burton Award finalist sharing his journey as the seminal leader behind the formation of Chinook Therapeutics. Tom’s business development leadership resulted in Chinook acquiring atrasentan from Abbvie in 2019 and after repositioning and advancing the asset for IgA nephropathy, Chinook was ultimately bought by Novartis in 2023 for up to US$3.5 billion. This acquisition is among the largest ever of a Canadian biotechnology company. The Bloom Burton Award honours an individual scientist, inventor, executive, entrepreneur, industry leader, or policy maker who made the greatest contribution to Canada’s innovative healthcare industry in the previous year. Nominees are accepted from any of the biotechnology, pharmaceutical, medical device, diagnostic/imaging, research instrumentation, consumer health, services or healthcare IT sectors, and equal consideration is given to contributions across any stage of development – from discovery to commercial end markets. The Bloom Burton Award winner is chosen by an esteemed panel of judges, all of whom are respected international leaders in healthcare investment, entrepreneurship and journalism. Learn more about Bloom Burton & Co. at www.bloomburton.com